Online inquiry

IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9432MR)

This product GTTS-WQ9432MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets KLRC1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001304448.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3821
UniProt ID P26715
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9432MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4905MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ13500MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRX002
GTTS-WQ3816MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ6770MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DS-1062
GTTS-WQ7574MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ12970MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ6822MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ7122MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW